+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Economic Evaluation of Riociguat in Patients with Inoperable or Residual Chronic Thromboembolic Pulmonary Hypertension



Economic Evaluation of Riociguat in Patients with Inoperable or Residual Chronic Thromboembolic Pulmonary Hypertension



Kardiologiia 55(3): 33-40



to undertake economic evaluation of riociguat in comparison with standard practice of treating patients with inoperable or residual chronic thromboembolic pulmonary hypertension (CTEPH) in Russian healthcare. METHODS. Standard practice was revealed by means of peer interview. It comprised bosentan monotherapy with addition of sildenafil in case of disease progression. Difference in efficacy between riociguat and bosentan was established through the indirect comparison based on the results of randomized controlled trials. Difference in costs of CTEPH treatment with riociguat and standard practice eas estimated in the Markov model that simulated changes in disease functional class (FC). Direct medical costs were considered and included drugs prescriptions, in-patient and out-patient medical care. Probabilistic sensitivity analysis was conducted. The results of indirect comparison suggest statistically significant higher probability of favorable outcomes in case of treatment with riociguat: improvement by ≥ 1 FC (difference in proportions = 14.8% with 95% confidence interval from 0.1 to 29.5; p = 0.048) and increase of distance in 6-minute walking distance (mean difference = 42.9 m with 95% confidence interval from 10.5 to 75.3; p = 0.009). In base-case scenario difference in costs between riociguat and standard practice was 60,646.15 RUB per 1 patient per year in favor of the former. Riociguat costs were lower in 94.4% of sensitivity analysis cycles. In 72.5% of sensitivity analysis cycles costs difference in favor of riociguat was at least half of that in in base-case. In 47.3% of sensitivity analysis costs difference in favor of riociguat was equal or higher to that in base-case. The results of modeling suggest that in Russian healthcare treatment of CTEPH with riociguat is characterized by higher efficacy at lower costs.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057685339

Download citation: RISBibTeXText

PMID: 26320288


Related references

Switching from sildenafil to riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension. International Journal of Cardiology 277: 239, 2019

Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulmonary Circulation 8(3): 2045894018783996, 2018

Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics. International Journal of Cardiology 269: 283-288, 2018

Response to letter from dr Altmayer regarding publication "Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics". International Journal of Cardiology 276: 240-241, 2019

Inoperable chronic thromboembolic pulmonary hypertension treated with riociguat: A case study. Revista Portuguesa de Cardiologia 34(12): 777.E1, 2015

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. Heart 103(8): 599-606, 2017

Home-based pulmonary rehabilitation in patients with inoperable or residual chronic thromboembolic pulmonary hypertension: a preliminary study. Respiratory Investigation 52(6): 357-364, 2014

Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. Journal of the American College of Cardiology 52(25): 2127-2134, 2008

Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Pulmonary Circulation 6(Suppl 1): S86-S96, 2016

Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Respiratory Medicine 129: 124-129, 2017

Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension. American Health and Drug Benefits 7(9): 479-487, 2014

Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. International Journal of Cardiology 195: 19-26, 2015

Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension. Drugs 74(17): 2065-2078, 2014

Successful Transition from Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study. Heart Lung and Circulation 2019:, 2019

Effect Of Riociguat On Right Ventricular Function In Patients With Chronic Thromboembolic Pulmonary Hypertension. Chest 154(4): 1065A-1066A, 2018